SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polygon

Polygon is trending due to a notable surge in network usage and on-chain revenue, bolstered by initiatives like the Open Money Stack and consistent token burning. The community is expressing strong bullish sentiment, often citing its perceived undervaluation against rivals and actively discussing a potential return to its familiar MATIC ticker.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing high investor interest driven by its recent balance sheet strengthening through debt conversion and a notable multi-billion dollar task order win. While many in the community are speculating on an 'infinity short squeeze' due to reported high cost-to-borrow and low share availability, others are expressing concerns over recent share registration filings and potential dilution, leading to a highly volatile and polarized sentiment.

SuperCom Ltd. engages in the provision of traditional and digital identity solutions. It offers identification, tracking, and security products to government, private and public organization. It operates through the following divisions: e-Gov, Internet of Things (IoT), and Cyber Security. The e-Gov division provides solutions for traditional and biometrics enrollment, personalization, issuance and border control services. The IoT division products and services reliably identify, track, and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles, and monitored objects. The Cyber Security division is involved in the comprehensive solutions to protect the organization's sensitive data residing on servers, laptops, and detachable devices. The company was founded by Jack Hasan and Eli Rozen on July 4, 1988 and is headquartered in Tel Aviv, Israel.

SuperCom Ltd

SuperCom is trending as it secures significant new national electronic monitoring contracts, including a $7 million project in Germany and expansion into numerous U.S. states, effectively displacing incumbent technology providers. The community is actively engaged in discussions around these growing contracts and the company's strong profit margins, with many speculating on a potential game-changing federal deal, such as an ICE/ISAP contract, that could trigger a substantial revaluation given its remarkably low float.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is a top trending stock as investors actively debate the potential impact of proposed credit card interest rate caps, with many arguing such measures primarily affect card issuers rather than Visa's transaction-based revenue. The company also recently reported strong earnings, bolstered by continued global payment volume growth and strategic advancements in stablecoin settlements. Community discussions highlight Visa's resilient network effect and its expanding role in a rapidly evolving digital payments landscape.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a top trending ticker after a Bank of America downgrade and news of Amazon Pharmacy offering Novo Nordisk's oral GLP-1 directly, intensifying competition in the weight loss sector. Community sentiment is deeply divided, with many bears highlighting overvaluation and lack of a moat, while bulls see a compelling buying opportunity and anticipate a strong long-term rebound for the telehealth platform.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is generating significant buzz due to recent government contract awards for its BioThrax anthrax vaccine and expanded manufacturing capabilities for raxibacumab, solidifying its position in national biodefense. The community is actively discussing potential for increased Narcan contracts driven by policy changes, with many investors anticipating substantial future gains despite past volatility and ongoing debates around short interest.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is actively restructuring its debt profile through a significant asset sale and ongoing refinancing efforts, which are seen as critical steps toward improving its financial health. This strategic pivot aims to sharpen its focus on high-margin enterprise services, particularly leveraging its extensive fiber network to support growing AI infrastructure needs and deepen partnerships with major tech companies. The community is buzzing about Lumen's long-term potential in the AI-driven landscape, with many viewing it as an undervalued play despite recent market volatility and executive changes.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is gaining significant attention following robust Black Friday sales growth and its strategic move to launch KlarnaUSD, a dollar-backed stablecoin, signaling a strong push into crypto payments and Web3 banking. While recent earnings reflected a temporary profitability lag due to upfront credit loss provisions, the company's accelerating user growth, low delinquency rates, and ambitious vision as an AI-first neobank are driving strong community optimism. Investors are actively debating Klarna's undervalued position and its potential to disrupt traditional finance amidst evolving consumer spending habits and a competitive Buy Now, Pay Later market.

Global X Funds - Global X Silver Miners ETF

Silver is trending due to persistent supply deficits, surging industrial demand from sectors like solar and EVs, and geopolitical influences on physical metal flows, fundamentally shifting its market dynamics. Community discussion highlights the metal's resilience to short-term market fluctuations and rebalancing events, with many anticipating a significant catch-up rally for silver miners (SIL) given their perceived undervaluation relative to the rising spot price.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is a top trending stock following a significant multibillion-dollar fuel cell purchase agreement with American Electric Power, alongside a substantial microgrid deal with Quanta. The community is abuzz about how these contracts underscore BE's crucial role in providing immediate, on-site power solutions for the rapidly expanding AI data center infrastructure, driving discussions around its growth potential despite its historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Healthcare Stocks To Watch Now - January 9th

UnitedHealth Group, Hims & Hers Health, and Johnson & Johnson are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly...

<ul class="summary-bullets"><li>Dudum said individuals are taking greater control of care through DTC access, preventive health, and wider use of AI.</li><li>BofA and Citi cut targets, citing margin pressure and a heavy investment outlook for 2026.</li><li>Novo’s broader rollout of oral Wegovy intensified competition in the GLP-1 market.</li></ul><p>Hims &amp; Hers Health CEO Andrew Dudum said the company is leaning into a consumer-led healthcare model in 2026, even as Wall Street grows more cautious about margins and near-term earnings pressure.</p><h2 class="st-heading-2"><strong>Dudum Sees AI As Key Focus</strong></h2><p>In a blog post on Thursday, Dudum said healthcare is moving toward personalized models that give individuals greater control over their care. He pointed to the growing role of direct-to-consumer channels, a rising emphasis on preventive and longevity-focused care, and broader use of AI to improve access and personalization.</p><p>He said there is a growing demand for easier access, lower prices and more personalized care, as well as heightened interest in early testing, diagnostics and continuous health tracking. Dudum added that AI is also being used to minimize friction in care delivery and enable more reliable engagement between consumers and providers.</p><h2 class="st-heading-2"><strong>OpenAI Pushes Into Healthcare</strong></h2><p>The development comes as large technology platforms increase their presence in healthcare.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/open-ai-launches-chatgpt-health/cmxzOpYR42A">OpenAI on Wednesday launched ChatGPT Health</a>, which helps users blend health information with AI-driven insights.</p><p>OpenAI said users can connect their electronic health records and fitness apps, such as Apple Health, Function and MyFitnessPal, securely to have ChatGPT help them make sense of test results and guide their health regimens in light of personal trends. The company said ChatGPT Health was developed over two years in collaboration with more than 260 physicians.</p><h2 class="st-heading-2"><strong>Wall Street Turns Cautious</strong></h2><p>On Thursday, Bank of America Securities (BofA) lowered its price target on Hims &amp; Hers to $29 from $32 and maintained an 'Underperform' rating, saying expectations for 2026 appear too optimistic.</p><p>The firm said consensus forecasts for sales and earnings before interest, taxes, depreciation, and amortization (EBITDA) margins are elevated, describing 2026 as a “big investment year” for the company. BofA added that it sees downside risk to 2026 revenue and margins, with negative earnings revisions likely in the coming months.</p><p><a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-enters-2026-on-solid-ground-stock-rises-even-after-novo-nordisk-leaves-it-off-wegovy-partner-list/cmxw0eER4Rq">Citigroup also maintained a ‘Sell’ rating&nbsp;</a>with a $30 price target, pointing to competitive pressures following a move by Novo Nordisk, which said its oral Wegovy pill is now broadly available in the U.S., with prices starting at $149 a month for certain doses and as low as $25 for some commercially insured patients.</p><p>Citi noted that Hims was again excluded from Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx, likely reflecting disagreements around Hims’ compounded semaglutide strategy. The firm added that broader access to oral Wegovy could weigh on Hims’ GLP-1 offering this year.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Hims was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_aa9782247d.webp" alt="hims ss.png" width="975" height="144"><figcaption>HIMS sentiment and message volume as of January 9| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 32% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year

The development follows OpenAI’s rollout of ChatGPT Health, which helps users blend health information with AI-driven insights.

Equity

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?

HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.

Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts

Hims & Hers Health, Inc. (HIMS) reached $35.45 at the closing of the latest trading day, reflecting a +2.12% change compared to its last close.

Best Healthcare Stocks To Follow Today - January 6th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Tempus AI, Novartis, and Hims & Hers Health are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul><p>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.</p><p>The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.</p><h2 class="st-heading-2"><strong>Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</strong></h2><p>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.</p><p>Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.</p><h2 class="st-heading-2"><strong>Broader Growth Drivers Remain in Focus</strong></h2><p>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.</p><p>Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;</p><p>Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.</p><p>In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.</p><h2 class="st-heading-2"><strong>Investors Look Beyond Near-Term GLP-1 Pressure</strong></h2><p>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.</p><p>Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure><p>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”</p><p><stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl></p><p>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.</p><p><stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl></p><p><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Best Healthcare Stocks To Consider - January 5th

UnitedHealth Group, Johnson & Johnson, Hims & Hers Health, McKesson, Intuitive Surgical, HCA Healthcare, and Tempus AI are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization

HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.

Promising Healthcare Stocks To Keep An Eye On - January 4th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Hims & Hers Health, Ironwood Pharmaceuticals, and Tempus AI are the seven Healthcare stocks to watch today, according to...

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

Traders are intensely debating key support and resistance levels, with many eyes on the $25 mark for potential entries and major short covers.

Concerns are rising as Amazon Pharmacy's offering of Wegovy at competitive prices intensifies competition in the GLP-1 weight loss market, challenging the company's 'moat.'

Investors are increasingly criticizing management and the CEO for the recent significant stock drop and perceived lack of communication during a period of extreme volatility.

The stock is experiencing overwhelming negative sentiment, with many declaring it 'garbage' and predicting further declines amidst widespread frustration and accusations of manipulation.

Despite the current downturn, some long-term investors maintain a bullish outlook, pointing to strong fundamentals, subscriber growth, and expansion into new verticals.

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HIMS News

HIMSHims & Hers Health Inc